Menotropins

Menotropins Brand Names- Menopur | Repronex

What is Menotropins

Menotropins are purified combination preparations of the human pituitary gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Menotropins are sometimes referred to as human menopausal gonadotropins or hMG.

Menotropins are obtained from the urine of postmenopausal women; they are then standardized and purified in accordance with standards established in 1964 by the World Health Organization.

Menotropins are used in combination with chorionic gonadotropin (hCG). Clinical uses include stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and induction of ovulation in anovulatory females.

Menotropins are also used in controlled ovarian hyperstimulation protocols for assisted reproductive technology (ART) procedures such as in vitro fertilization (IVF). They are also administered to regulate the timing of ovulation in those patients receiving donor insemination.

Menotropins therapy is associated with increased rates of multiple births (>= 20%) compared to the general population (1%).

Fifteen percent of multiple gestations are twins; 5% result in triplets or more. In the comparison of menotropins (hMG) to urofollitropin or recombinant FSH preparations, all have similar incidences of major side effects like ovarian hyperstimulation.

The FDA first approved menotropins for use in 1975. FDA-approved in August 1999, Repronex® was the first menotropins formulation approved for subcutaneous administration.

Menopur®, a highly purified menotropins product, was FDA-approved in October 2004, and this product is administered via subcutaneous injection.

Highly purified products like Menopur® are less likely to induce injection site reactions; in clinical studies, this highly purified product produced comparable pregnancy rates to recombinant FSH products.

Indications

  • hypogonadism
  • infertility
  • oligospermia

For the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia

Side Effects

  1. abdominal pain
  2. acute respiratory distress syndrome (ARDS)
  3. anaphylactoid reactions
  4. angioedema
  5. back pain
  6. constipation
  7. cough
  8. diarrhea
  9. dizziness
  10. dyspnea
  11. erythema
  12. fatigue
  13. fever
  14. flushing
  15. gynecomastia
  16. headache
  17. hot flashes
  18. injection site reaction
  19. malaise
  20. mastalgia
  21. migraine
  22. nausea
  23. ovarian enlargement
  24. ovarian hyperstimulation syndrome (OHSS)
  25. pelvic pain
  26. phlebitis
  27. pruritus
  28. pulmonary embolism
  29. rash
  30. sinus tachycardia
  31. stroke
  32. tachypnea
  33. thromboembolism
  34. thrombosis
  35. urticaria
  36. vaginal bleeding
  37. vomiting

Monitoring Parameters

  • pelvic exam
  • pelvic ultrasound
  • serum estradiol concentrations
  • serum gonadotropin concentrations
  • serum testosterone concentrations
  • sperm count
  • urinary gonadotropin concentrations

Contraindications

  • adrenal insufficiency
  • ascites
  • breast-feeding
  • children
  • dysfunctional uterine bleeding
  • endometriosis
  • geriatric
  • neoplastic disease
  • obesity
  • ovarian cyst
  • ovarian failure
  • pituitary adenoma
  • polycystic ovary syndrome
  • pregnancy
  • testicular failure
  • thromboembolic disease
  • thrombophlebitis
  • thyroid disease
  • tobacco smoking
  • uterine leiomyomata

Interactions

There are no drug interactions associated with Menotropins products.

You cannot copy content of this page